3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Carcinoma, Neuroendocrine
1
Carcinoid Tumor
1
Interventions
lutetium Lu 177 dotatate
15
Everolimus
11
Nivolumab
10
pembrolizumab
9
Temozolomide
9
Capecitabine
7
cabozantinib
6
Sunitinib
6
lenvatinib
5
lanreotide
4
gallium Ga 68 dotatate
4
Ipilimumab
4
Etoposide
4
Carboplatin
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
telotristat ethyl
3
pazopanib
3
avelumab
3
Octreotide
3
Magnetic Resonance Spectroscopy
3
Injections
3
Cyclophosphamide
3
Cisplatin
3
Bevacizumab
3
surufatinib
2
sintilimab
2
fosbretabulin
2
fludarabine
2
Specimen Handling
2
Sorafenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neuroendocrine Tumors
×
177Lu-octreotate
×
Clear all
NCT02754297
2024-08-21
P-PRRT
CHU de Quebec-Universite Laval
Phase 2
Active not recruiting
275 enrolled